Plasminogen activator-inhibitor C-1 (PAI-1) plays a critical role in the regulation of fibrinolysis, serving as the primary inhibitor of tissue-type plasminogen activator. Elevated levels of PAI-1 are a risk factor for recurrent myocardial infarction, and locally increased PAI-1 expression has been described in atherosclerotic human arteries. Recent studies have shown that the administration of angiotensin converting enzyme inhibitors reduces the risk of recurrent myocardial infarction in selected patients. Since angiotensin II (Ang IT) has been reported to induce PAI-1 production in cultured astrocytes, we have hypothesized that one mechanism that may contribute to the beneficial effect of angiotensin converting enzyme inhibitors is an effect on fibrinolytic balance. In the present study, we examined the interaction of Ang II with cultured bovine aortic endothelial cells (BAECs) and the effects of this peptide on the production of PAI-1. 
Introduction
Plasminogen activator inhibitor-I (PAI-1)1 is a member of the superfamily of serine protease inhibitors (serpins) and is the main physiological inhibitor of tissue-type plasminogen activator (t-PA) ( 1, 2). The endothelium is likely to be a major source of PAI-I in the circulation, although the liver and platelets also contribute to the PAI-I levels measured in plasma (3, 4) . Elevated levels of PAI-I have been implicated in the pathogenesis of thromboembolic disease and, in particular, may contribute to the risk of reinfarction in patients that have suffered a previous myocardial infarction (5, 6) . Furthermore, increased PAI-1 expression has been observed in atherosclerotic human arteries (7) . Conversely, PAI-I deficiencies are associated with a bleeding tendency in humans (8, 9) . Multiple factors have been identified that play a role in the regulation of PAI-I synthesis and secretion. PAI-I is an acute-phase reactant (10) , and plasma levels of the protein are elevated postoperatively ( 11 ) and during septicemia ( 12) . Agents that are known to regulate endothelial PAI-I production include endotoxin (13) , TNF (14) , TGF-/3 (14) , thrombin (15) , and lipoprotein (a) (16) .
We have recently shown that the infusion of physiological amounts of angiotensin II (Ang II) promotes a rapid and dosedependent increases in plasma PAI-i levels in humans (17) . Ang II is a potent effector peptide of the renin-angiotensin system and exerts a wide variety of actions on the cardiovascular, renal, endocrine, and central nervous systems (18, 19) . Furthermore, the biological responses induced by Ang II are varied and tissue dependent ( 18) . Ang II exerts its effects via binding to specific receptors located on cell membranes ( 19), and at least two major classes and several additional subtypes have been identified (20) . These receptor subtypes can be differentiated by their biochemical properties and by their affinity for synthetic ligands. The cDNA for the type 1 (AT1) and type 2 (AT2) Ang II receptors have been cloned (21) (22) (23) (24) . These receptors are both members of the superfamily of G-proteincoupled receptors containing seven transmembrane domains and are -32% homologous at the protein level (23) . Although both receptors bind Ang II saturably and specifically, the AT1 appears to mediate most of the physiologic effects of Ang 11 (20) .
Endothelial cells possess many of the constituents of the renin-angiotensin system including angiotensin converting enzyme (ACE), angiotensinogen, renin, and receptors for angiotensin (25) (26) (27) . Ang II saturably and reversibly binds to the surface of cultured vascular endothelial cells via a single class of high affinity binding sites (27) , although the characteristics of the endothelial binding do not allow it to be categorized as typical of an AT, or AT2 receptor subtype. There is some evidence to suggest that this interaction has physiological consequences, since endothelial prostaglandin production is enhanced after exposure to Ang II (28) . Furthermore, there is evidence of a regulatory linkage between the renin-angiotensin system and fibrinolysis. Interruption of the endothelial autocrine angiotensin system with ACE inhibition promotes endothelial migration and urokinase production in vitro (29) . Recently, Ang II has been reported to stimulate selectively the production of PAI-I in cultured murine astrocytes (30) . The present study was designed to determine whether Ang II plays a role in the regulation of the expression of PAI-I in cultured endothelial cells. Cell culture. Bovine aortic endothelial cells (BAECs) were harvested, using 0.1% collagenase, from fresh bovine aortas (31 ); primary cultures were initiated simultaneously from six to eight aortas. After reaching confluence, cells were detached using trypsin/EDTA, pooled, and serially propagated in DME supplemented with penicillin (50 U/ ml), streptomycin (50 Mg/ml), and 20% bovine calf serum. The cells were incubated at 37°C in humidified 95% air/5% CO2 and routinely passaged with a split ratio of 1 (32) . HUVECs were grown on gelatin-coated plates in DME containing 25 mM Hepes buffer and 2.0 mM glutamine supplemented with 20% FBS, 50 Mg/ml endothelial mitogen, 50 U/ml penicillin, and 50 ,ug/ml streptomycin. For experimental studies, BAECs were grown to confluence in 100-mm plastic culture dishes, washed with sterile PBS, and incubated overnight in serum-free medium that was otherwise complete. The next day, the confluent monolayers were washed two times with PBS and incubated with serum-free media supplemented with Ang II freshly reconstituted in DME at the concentrations and for the durations indicated in the following section.
Methods
Endotoxin assay. The Ang II preparations used in these experiments were > 98% pure and generated single peaks by HPLC analysis performed by the manufacturers. These peptides were assayed for the presence of contaminating endotoxin using the Limulus Amebocyte Lysate assay (PyrogentR, BioWhittaker), according to the manufacturer's instructions (33) . This assay has a sensitivity of 0.06 endotoxin units per ml, which corresponds to a concentration of 6.0 pg/ml, with 10 endotoxin units equal to 1.0 ng. The assay is calibrated using a preparation of purified endotoxin from Escherichia coli strain 055:B5. There was no detectable endotoxin present in a 1.0-MM/liter concentration of Ang II reconstituted in endotoxin-free water.
Binding assays. Specific binding of '25I-Ang II with BAECs was performed as described by Patel et al. (27) . Confluent (34) . Radioactivity was determined in a gamma counter (Packard Instrument Co., Meriden, CT) with a counting efficiency of 74%. Specific binding was defined as the difference between total and nonspecific binding. Nonspecific binding was determined by the addition of a 100-fold molar excess of unlabeled Ang II.
PAI-I antigen measurements. Conditioned medium was collected after the indicated times, centrifuged to remove cellular debris, and stored for -48 h at -20°C until assays were performed. PAI-1 antigen concentrations were determined with a commercially available ELISA (TintElizeR PAI-1, Biopool, Umea, Sweden) specific for PAI-I (free or complexed) (35) using a double antibody technique, in accordance with the manufacturer's instructions, as previously described (36) .
RNA isolation and measurement. Total cellular RNA was prepared from confluent cultures of BAECs by the acid guanidinium thiocyanate method (37), followed by isopropanol precipitation (RNAzol, Cinna Biotecx, Houston, TX). RNA pellets were resuspended in DEPC-treated H20, and their concentration was determined by absorbance at 260 nm. The relative amount of specific mRNA present in the samples was quantified via either slot blot (38) or Northern (39) hybridization analysis. For slot blot studies, total RNA was denatured with 6 M glyoxal for 1 h at 50°C. The RNA (10 Mlg) was applied to a nylon membrane (Zeta ProbeR, Bio-Rad Laboratories, Richmond, CA) using a slot blot filtration apparatus (Bio-Dot SF, Bio-Rad Laboratories). After application of the samples, membranes were baked for 2 h at 80°C under vacuum. For Northern hybridization studies, RNA (10 Mg) was size fractionated on 1.2% formamide agarose gels, transferred to nylon filters, and baked as previously described. The membranes were prewashed in 0.1 x SSC, 0.5% SDS for 1 h at 65°C followed by prehybridization overnight at 42°C in the following mixture: 50% formamide, Sx SSC, 5x Denhardt's solution, 25 mM phosphate buffer, pH 7.4, 10% dextran sulfate, 1 mM EDTA, 1% SDS containing heat-denatured transfer RNA (500 Mg/ml), and sonicated, heat-denatured salmon sperm DNA (200 Mg/ml). Membranes were hybridized with cDNA probes labeled with 32P-labeled deoxycytidine triphosphate ([32P]dCTP) for 16-24 h at 42°C in a shaking water bath, washed using 0.1 x SSC, 0.1% SDS at 65°C, air dried, and exposed to XAR film (Eastman Kodak Co., Rochester, NY) with intensifying screens at -70°C. The relative intensity of the autoradiographic images was determined using transmission densitometry. Relative RNA loading was determined by examination of ethidium bromide-stained gels. Reflectance densitometry of the ethidium bromide-stained 28S bands was used for normalizing autoradiographic data.
cDNA probes. The PAI-l probe consisted of a 2.3-kb EcoRI fragment from pSP65, containing 32 Fig. 4 , Ang II induced a dose-dependent increase in PAI-1, maximally inducing an approximate threefold increase in PAI-I protein. The dose-response relationship between Ang TI and PAI-I production was highly statistically significant (P < 0.001).
Effects ofAng l on the expression of PAI-I mRNA. In these experiments, confluent cultures of BAECs were incubated for 6 h in the presence of various concentrations of Ang II. At the end of the experimental period, the cells were washed and solubilized, and total RNA was extracted as described. A representative autoradiogram derived from a Northern blot is shown in Fig. 5 (Fig. 5 B) . In these experiments, 10 M~g of total RNA was applied to each slot, with each slot containing RNA from separate dishes of BAECs. The results of these experiments are shown in Fig. 5 that the effect of Ang II on PAI-I expression is due to other contaminating factors present in the peptide preparation. Ang I (20 nM) induced PAI-1 mRNA levels to nearly the same extent as Ang II, but this effect was inhibited when the experiment was performed in the presence of captopril (1.0 ,tM) (data not shown).
To exclude the possibility that the effect of Ang II in inducing PAI-1 mRNA expression was species specific, similar experiments were performed using HUVECs (P2). These experiments were identical to those performed using BAECs except that the cells were not serum starved during the preinduction period, and the experiment was performed in the presence of 5% FBS. The results of a representative experiment are shown in Fig. 6 and indicate that exposure to Ang II increases PAI-I mRNA levels in HUVECs in a dose-dependent manner. Both PAI-I mRNA species were identifiable in the experiments performed using HUVECs.
Effects ofAng II on the accumulation of PAI-I mRNA as a function of time. In these experiments, cells were placed in serum-free media and exposed to 20 nM Ang II at time 0. Cells were lysed and total RNA was harvested after the indicated incubation periods. Northern blotting of total RNA revealed induction of a single species of PAI-I mRNA (-3.3 Fig. 7 A and exhibits an increase in PAI-I mRNA as a function of time after exposure of BAECs to Ang II. The autoradiograms were scanned by densitometry, and the values were normalized for RNA loading at each time point (Fig. 7 B) . To (2) (3) (4) (5) (6) (7) (8) ) and Ang IV (Ang 11 (3) (4) (5) (6) (7) (8) ) (27, 42) . The lack of potency of [Sar', Ile8] -Ang II as a competitive antagonist in these studies is unexpected, but suggests that one or both of the terminal residues of the peptide play an important role in the interaction of Ang II with endothelial cells. Additional studies will be required in order to clarify this observation. The previously reported failure of Ang II to alter cytosolic calcium levels in cultured endothelium (43) also supports the contention that the endothelial angiotensin receptor is not an AT1 subtype, since binding of Ang II to the AT1 is generally associated with the mobilization of intracellular calcium (20) . In recent studies, we have failed to identify the presence of AT1 receptor mRNA in Northern blots of total RNA from BAECs using a cDNA Autoradiographic data was quantified using transmission densitometry. Experiments were performed in triplicate 10.0 and means±SD are shown.
kb). A representative autoradiogram is shown in
probe (22) (30) . There are slight differences in the pattern of mRNA expressed by the BAECs and HUVECs: only a single RNA species is seen in the Northern blots from BAECs, whereas two species are seen in the experiments with HUVECs. In previous studies dealing with the regulation of the expression of PAI-I mRNA, the presence of two PAI-I transcripts is often reported, with the larger species containing additional 3' untranslated sequence that is not present in the smaller transcript (14) . The present findings may reflect the fact that the probe used in these studies was been compounded by the relatively stringent conditions that were used in the Northern blot experiments. Additionally, the PAI-i cDNA probe used in these experiments includes a significant portion of sequence from the 3' untranslated region of PAI-1-sequence that is present to a much greater extent in the larger (i.e., 3.3-kb) polyadenylated PAI-I transcript (14) .
Although there was a clear dose-response relationship between Ang II and PAI-I secretion in these studies using BAECs, the EC50 for this response was at least an order of magnitude higher than the Kd for the interaction. This finding may be explained as merely a result of the conditions under which the experiments were performed (and therefore artifactual), or it may be indicative of the fact that the transcriptional and translational/secretory mechanisms are independently controlled. Since we have previously shown that physiological concentrations of Ang TT can result in a rapid increase in plasma PAI-I levels (17) , this suggests that the former explanation may be correct. It is also possible that some of the observed effect of Ang II on PAI-I secretion could be due to a contaminating effect of endotoxin. The Ang TT preparations used in these studies had a LPS content of c 1.25 pg per ,tug of peptide, which corresponds to a LPS concentration of -1 pg/ml in the presence of an Ang II concentration of 1.0 MM. Although this level of LPS has previously been shown to have little or no effect on PAI-I expression ( 14) , some additive effect of endotoxin at the highest Ang TT concentrations cannot be entirely excluded. Such an effect may have in fact contributed to the biphasic contour of the dose-response curve shown in Fig. 4 .
A relationship between Ang TT and endothelial cell production of PAI-I is particularly interesting when considered in light of two large, recent clinical studies independently demonstrating that the administration of angiotensin converting enzyme (ACE) inhibitors to patients with left ventricular dysfunction reduces the incidence of recurrent myocardial infarction and unstable angina pectoris by > 20% (44, 45) . The mechanism of this newly recognized anti-ischemic effect of ACE inhibitors is unknown, but given previously published data correlating elevated PAI-i levels with an increased risk of reinfarction in survivors of myocardial infarction (6), we speculate that ACE 
